Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

CSFB Initiates Kosan With Outperform


CS First Boston initiates Kosan Biosciences (KOSN) coverage with outperform.

Analyst Michele Park says the company has two first-in-class anti-cancer drugs in Phase 1 and 2 trials in multiple settings. It is in a partnership with Roche to develop and commercialize its lead candidate KOS-862 (Epothiline D) in oncology, a proprietary polyketide drug discovery platform.

She notes all this potential for the development-stage company with over $200 million in market capitalization. She says KOS-862 is in two Phase 2 trials in second-line breast cancer and prostate cancer, and in many dose-escalating Phase 1b combination trials.

Park expects data from these studies to create positive catalysts for Kosan throughout 2005.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus